Gynecologic Oncology Reports最新文献

{"title":"Implementation of a stepwise process for somatic testing in patients with a new diagnosis of germline negative epithelial ovarian cancer","authors":"Casey L. Lawler ,&nbsp;Sara M. Klennert ,&nbsp;Kristin C. Cole ,&nbsp;Karen S. Schaepe ,&nbsp;Laura J. Ongie ,&nbsp;Megan E. Grudem ,&nbsp;Carolyn M. Klampe ,&nbsp;Myra J. Wick ,&nbsp;Vonda M. Wall ,&nbsp;Sanjna Rajput ,&nbsp;Clarissa L. Polen-De ,&nbsp;Amanika Kumar","doi":"10.1016/j.gore.2025.101935","DOIUrl":"10.1016/j.gore.2025.101935","url":null,"abstract":"<div><h3>Objective</h3><div>We sought to establish a process for increasing somatic tumor testing for patients with germline BRCA negative advanced stage epithelial ovarian cancer (EOC) and to gain insight into patients’ comprehension of their genetic testing.</div></div><div><h3>Methods</h3><div>A multidisciplinary team utilized quality improvement framework to address clinical needs. After implementation of a new somatic testing process, we compared the rates of genetic testing referral, germline testing and somatic testing recommendations between a historic cohort (January 1, 2019-June 20, 2019) and implementation cohort (October 1, 2020 – March 31, 2021). Patients diagnosed with stage III-IV EOC who underwent surgery were included for analysis. To explore patients’ comprehension of their genetic testing results, twenty-three patients in the historic cohort participated in semi-structured interviews.</div></div><div><h3>Results</h3><div>Patients with advanced stage EOC without a germline BRCA mutation received recommendations for somatic testing 53.5 % (23/43) of the time in the historic cohort. An improvement in the rate of somatic testing recommendations was seen in patients without a germline mutation in the implementation cohort (84.6 % [22/26], P = 0.010). There was no decrease in germline testing after implementation (90 % [63/70] and 96.3 % [52/54,] P = 0.30). Most patients (21/23) in the historic cohort were not aware that both germline and somatic testing were completed for their oncology care.</div></div><div><h3>Conclusion</h3><div>We successfully increased somatic testing recommendations in germline BRCA negative patients prior to completing upfront EOC treatment allowing for a timely, individualized discussion of maintenance PARP inhibitor use. Qualitative assessment of patients’ comprehension of genetic testing for EOC shows a deficit in patient knowledge.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101935"},"PeriodicalIF":1.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of racial differences in HER2 status and molecular subtype in grade 3 endometroid endometrial carcinoma","authors":"Sarah A. Ackroyd ,&nbsp;Gabrielle Sudilovsky ,&nbsp;Yan Che ,&nbsp;Jennifer A. Bennett ,&nbsp;S Diane Yamada ,&nbsp;Gini F Fleming","doi":"10.1016/j.gore.2025.101936","DOIUrl":"10.1016/j.gore.2025.101936","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize stage I-III Grade 3 endometroid endometrial cancer (Gr3 EEC) by molecular subtype and human epithelial growth factor receptor 2 (HER2) status and explore differences in characteristics by race.</div></div><div><h3>Methods</h3><div>We identified patients with a diagnosis of stage I-III Gr3 EEC from a single-institution health system cancer registry and pathologically confirmed the diagnosis. Review of the electronic health record was performed as needed to confirm patient characteristics. Next-generation sequencing (NGS) and immunohistochemical staining (IHC) for HER2 was performed on all primary tumors.</div></div><div><h3>Results</h3><div>Thirty-four primary cases remained classified as stage I-III Gr3 EEC after pathologic review and exclusion of cases lacking in-house primary tumor for re-review. Fifteen were categorized as microsatellite unstable (MSI; 44 %), 10 as copy number high (CNH; 29 %), six as polymerase E mutant (<em>POLE</em>mut; 17.6 %) and three as copy number low (CNL; 8.8 %). Thirteen patients were Black, 18 were White, and 3 had a race of “other and/or unknown”. HER2 status by IHC in the primary tumor was 0 (n = 7; 20.5 %), 1+ (n = 11; 32 %), 2+ (n = 14; 41 %), 3+ (n = 1; 3 %). There was no difference in the distribution of TCGA subtype or HER2 status by race.</div></div><div><h3>Conclusion</h3><div>In stage I-III stage Gr3 EEC HER2 positivity (3 + ) was uncommon, but expression at the 2 + level was frequent, and did not differ by race. In this limited sample, there were no differences in distribution of TCGA subtype amongst patients with grade 3 EEC. Other causes should be explored to explain reported differences in outcomes in EEC by race.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101936"},"PeriodicalIF":1.3,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): About three case reports","authors":"J. Benichou ,&nbsp;J. Varinot ,&nbsp;R. Bossi-Croci ,&nbsp;M. Bazot ,&nbsp;D. Sitbon ,&nbsp;M. Dahan ,&nbsp;C. Ferrier ,&nbsp;Y. Dabi ,&nbsp;C. Touboul ,&nbsp;J. Lotz ,&nbsp;E. Darai","doi":"10.1016/j.gore.2025.101932","DOIUrl":"10.1016/j.gore.2025.101932","url":null,"abstract":"<div><h3>Background</h3><div>Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive ovarian cancer affecting young women, typically associated with poor survival. We present three cases of SCCOHT and review the current literature regarding clinical features, diagnosis, management, and survival.</div></div><div><h3>Cases</h3><div>Three patients aged 16, 29, and 39 years were treated for ovarian masses. None presented with hypercalcemia. In case 1, MRI findings mimicked a mucinous cystadenocarcinoma, while the other two cases appeared as benign ovarian tumors. Following initial surgery and histological diagnosis of SCCOHT, all patients received comprehensive radical surgery, multi-agent chemotherapy, radiotherapy, and autologous stem cell transplantation. Two patients remain recurrence-free at 5 and 20 years, while the third has a 10-month follow-up. Genetic testing was performed in two patients, revealing no constitutional mutations in SMARCA4 or related genes.</div></div><div><h3>Conclusions</h3><div>These cases highlight the difficulty of establishing a preoperative diagnosis of SCCOHT. Unlike previous reports, our data suggest that intensive multimodal therapy can result in favourable outcomes for stage I SCCOHT. Further studies are needed to define optimal treatment strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101932"},"PeriodicalIF":1.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity management in the setting of endometrial cancer and hyperplasia: A narrative review","authors":"Natalie Moshayedi ,&nbsp;Kiran Clair ,&nbsp;Alex A. Francoeur","doi":"10.1016/j.gore.2025.101929","DOIUrl":"10.1016/j.gore.2025.101929","url":null,"abstract":"<div><div>Obesity is a well-established risk factor for endometrial cancer, driven by chronic inflammation, insulin resistance, and excess estrogen. As the global obesity epidemic continues to worsen, effective weight management plays a crucial role in reducing both incidence and progression. Recent pharmacotherapy advancements, particularly GLP-1 receptor agonists, show promising weight loss effects by modulating appetite and metabolism. Preclinical studies suggest these agents may also influence cancer progression, though further clinical research is needed. Bariatric surgery remains the most effective long-term intervention for severe obesity, offering significant metabolic and hormonal benefits. Weight loss surgery is associated with reduced cancer risk and improvements in molecular markers, though findings on specific biomarkers remain inconsistent. This narrative review explores emerging weight loss interventions, focusing on novel pharmacologic agents and bariatric surgery, and their impact on endometrial cancer risk and outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101929"},"PeriodicalIF":1.3,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of CT-PCI and CA-125 changes following neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A retrospective study from Vietnam","authors":"Ty Van Ngo ,&nbsp;Luc Tien Dao ,&nbsp;Anh Dinh Tran ,&nbsp;Chinh Tri Le ,&nbsp;Hau Xuan Nguyen ,&nbsp;Huyen Thi Phung","doi":"10.1016/j.gore.2025.101927","DOIUrl":"10.1016/j.gore.2025.101927","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to evaluate the prognostic significance of CT-based Peritoneal Cancer Index (CT-PCI) scores and serum CA-125 levels, assessed before and after neoadjuvant chemotherapy (NACT), in relation to surgical outcomes and survival among patients with advanced-stage epithelial ovarian cancer (EOC).</div></div><div><h3>Methods</h3><div>This retrospective study included 96 patients with advanced EOC who received NACT followed by interval debulking surgery (IDS) at Hanoi Medical University Hospital and the National Cancer Hospital (K Hospital), Vietnam, between 2019 and 2024. CT-PCI scores and CA-125 levels were assessed both pre- and post-NACT. The associations between these changes and surgical outcomes, particularly optimal cytoreduction, were analyzed.</div></div><div><h3>Results</h3><div>The mean age was 59.17 years (SD = 9.78), with 94.8 % of patients diagnosed with high-grade serous carcinoma and 51.0 % classified as FIGO stage IIIC. Median CT-PCI scores decreased from 14.0 (IQR: 7.0–19.0) to 4.0 (IQR: 2.0–8.0), and median CA-125 levels declined from 1248 U/ml (IQR: 389–2855) to 31.25 U/ml (IQR: 16.75–147.3) post-treatment (both p &lt; 0.01). Optimal cytoreduction was achieved in 84.4 % of cases. Post-NACT CT-PCI scores and CA-125 levels &gt; 35 U/ml were significantly associated with suboptimal cytoreduction (cOR = 1.15, 95 % CI: 1.03–1.27, p = 0.01; and cOR = 5.26, 95 % CI: 1.38–33.00, p = 0.02, respectively). Median progression-free survival was 20.5 months; median overall survival was 36.7 months.</div></div><div><h3>Conclusion</h3><div>Post-treatment CT-PCI scores and CA-125 levels are valuable prognostic indicators in advanced epithelial ovarian cancer. Their reduction following NACT correlates significantly with improved progression-free and overall survival. These findings support their potential role in informing clinical decision-making and tailoring personalized treatment strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101927"},"PeriodicalIF":1.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-related myocarditis during DUO-E regimen for endometrial cancer: The first case report in gynecologic oncology","authors":"Eri Yamabe ,&nbsp;Hironori Yamamoto ,&nbsp;Keita Asano ,&nbsp;Taku Yasui ,&nbsp;Masashi Fujita ,&nbsp;Tsuyoshi Hisa ,&nbsp;Miho Kitai","doi":"10.1016/j.gore.2025.101924","DOIUrl":"10.1016/j.gore.2025.101924","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) are increasingly used in gynecologic oncology, with the DUO-E regimen—carboplatin, paclitaxel, and durvalumab—recently approved in Japan for advanced or recurrent endometrial cancer. However, ICI-related myocarditis (ICI-M) is a rare but potentially fatal adverse event requiring prompt recognition and treatment.</div></div><div><h3>Case Presentation</h3><div>A 74-year-old woman with advanced endometrial cancer developed ICI-M following four cycles of DUO-E therapy. Sixteen days post-treatment, she presented with fever and fatigue. Markedly elevated troponin I (39.8 ng/mL), new-onset complete right bundle branch block, and a reduced left ventricular ejection fraction (40 %) raised suspicion for ICI-M. Endomyocardial biopsy revealed diffuse CD8 + T-cell infiltration and myocyte necrosis, consistent with active myocarditis. High-dose methylprednisolone (1 g/day) was promptly initiated, resulting in rapid cardiac recovery and clinical stabilization. Chemotherapy was successfully resumed after steroid tapering.</div></div><div><h3>Conclusion</h3><div>This is the first reported case of ICI-M during DUO-E therapy for endometrial cancer. It underscores the importance of early clinical suspicion, rapid multidisciplinary collaboration, and timely intervention in managing ICI-M, particularly in high-risk patients. Continuous vigilance is warranted throughout the course of ICI therapy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101924"},"PeriodicalIF":1.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144890854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series","authors":"Andreea I Dinicu,&nbsp;Peter G Rose","doi":"10.1016/j.gore.2025.101925","DOIUrl":"10.1016/j.gore.2025.101925","url":null,"abstract":"<div><h3>Objective</h3><div>Carcinosarcoma an aggressive subtype of ovarian cancer. While treatment consists primarily of cytoreductive surgery followed by platinum-based chemotherapy, maintenance therapy can also be considered. Limited data exists on the use of<!--> <!-->poly ADP-ribose polymerase (PARP) inhibitors in ovarian carcinosarcoma, though this has been anecdotally successful among a small number of patients. In this case series, we present four patients with advanced or recurrent ovarian carcinosarcoma who were successfully treated with PARP inhibitors.</div></div><div><h3>Methods</h3><div>This case series included patients ages 18 or older who were diagnosed with ovarian carcinosarcoma and received maintenance therapy with a PARP inhibitor. Patient demographic and oncologic data was extracted. Cases were presented in detail and descriptive statistics were performed.<!--> <!-->A literature review was conducted to identify additional published case reports.</div></div><div><h3>Results</h3><div>Four patients from our institution were identified upon review of the electronic medical record. Age range at time of diagnosis<!--> <!-->was 47 to 74.<!--> <!-->Of the four patients, three (75 %) were treated in the upfront setting and one (25 %) was treated in the recurrent setting. Two patients were positive for homologous recombination deficiency, and another was positive for a<!--> <em>CHEK2</em> <!-->mutation. Progression-free survival (PFS) while receiving treatment with a PARP inhibitor ranged from 13 to 72 months. One patient passed away 46 months after diagnosis, while three other patients remain alive from 25 to 108 months.</div></div><div><h3>Conclusions</h3><div>We present a series of patients with ovarian carcinosarcoma who were treated with PARP inhibitors at our institution and saw clinically meaningful benefits, both in the upfront and recurrent setting.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101925"},"PeriodicalIF":1.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of neuroendocrine carcinoma of the cervix: Retrospective review from a large academic cancer centre","authors":"Jason Fernandes ,&nbsp;Anjelica Hodgson ,&nbsp;Kathy Han ,&nbsp;Michael Milosevic ,&nbsp;Jelena Lukovic ,&nbsp;Stephanie Lheureux ,&nbsp;Sarah E Ferguson ,&nbsp;Anna Santiago ,&nbsp;Jennifer Croke","doi":"10.1016/j.gore.2025.101933","DOIUrl":"10.1016/j.gore.2025.101933","url":null,"abstract":"<div><h3>Objective</h3><div>Neuroendocrine cervical carcinomas are a rare but aggressive malignancy associated with a poor prognosis and there is limited evidence to guide clinical decision-making. Our objective was to evaluate the patterns of practice and clinical outcomes of patients diagnosed with neuroendocrine cervical carcinoma.</div></div><div><h3>Methods</h3><div>This was a retrospective chart review of patients diagnosed with neuroendocrine cervical carcinoma between 2007 and 2023. Demographic, treatment, and outcome data were extracted from the medical records and summarized using descriptive statistics.</div></div><div><h3>Results</h3><div>In total 32 patients were identified. Median follow-up was 14.5 months, and median age at diagnosis was 52 (range 21–89), 31.3 % (10/32) were stage IVB at time of diagnosis. Primary treatment consisted of surgery in 10 patients (31.3 %) and chemo-radiation in 15 patients (46.9 %), with the remainder of patients (7/32, 21.9 %) receiving upfront palliative therapy. Adjuvant chemotherapy typically consisted of a combination of cisplatin and etoposide. Median OS for the full cohort was 19 months (2-year OS 39 %, 2-year LR 9 %, 2-year LRR 9 %). Primary surgery was generally offered to patients with earlier stage disease (IA2-IIA1) relative to primary chemoradiotherapy (IB1-IVB). Patients treated with primary surgery had significantly higher median OS compared to those treated with primary chemoradiotherapy (39 vs 19 months, p = 0.04). Treatment failure usually consistent of distant metastatic relapse (15/20, 75 %).</div></div><div><h3>Conclusion</h3><div>In our single institution review of neuroendocrine carcinoma of the cervix, primary surgery was associated with improved OS; however, our sample size was small with a bias to offering upfront surgery to patients with earlier stage disease.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101933"},"PeriodicalIF":1.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous transesophageal gastrostomy in gynecologic oncology patients with symptomatic malignant bowel obstruction: A case series","authors":"Leslie Panella ,&nbsp;Megan Gorman ,&nbsp;Divya Gowthaman ,&nbsp;Gary L. Goldberg ,&nbsp;Marina Frimer ,&nbsp;Daniel Putterman ,&nbsp;Jill S. Whyte","doi":"10.1016/j.gore.2025.101931","DOIUrl":"10.1016/j.gore.2025.101931","url":null,"abstract":"<div><h3>Introduction</h3><div>Malignant bowel obstruction (MBO) is a frequent complication in patients with advanced gynecologic malignancies. Percutaneous transesophageal gastrostomy tubes (PTEG) were developed as an alternative in patients when percutaneous endoscopic gastrostomy (PEG) is technically difficult or clinically contraindicated.</div></div><div><h3>Clinical cases</h3><div>Here we present three cases of women with gynecologic cancers with MBO who failed conservative or medical management and had a PTEG placed for palliative gastric decompression. No major complications were noted.</div></div><div><h3>Materials and methods</h3><div>The procedures were successfully performed under general anesthesia by Interventional Radiologists. Under ultrasound and fluoroscopic guidance, a multipurpose drainage catheter was placed through the neck into the esophagus and positioned into the stomach. The catheter was then connected to drainage. Technical success was achieved in all the patients.</div></div><div><h3>Discussion</h3><div>There are few palliative options for gastric decompression in patients who have advanced gynecologic malignancies. Both PEG and long-term nasogastric tube use have well-documented complications, especially in patients with large tumor burden and ascites. PTEG has been developed as a safe alternative with a low rate of complications and effective symptomatic relief in this patient population.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101931"},"PeriodicalIF":1.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Massive diaphragmectomy combined with pericardiectomy for ovarian cancer: a case report","authors":"Yuanyuan Guo ,&nbsp;Liang Chen ,&nbsp;Jianlei Wu ,&nbsp;Fang Zhang ,&nbsp;Yan Wang ,&nbsp;Nuo Xu","doi":"10.1016/j.gore.2025.101928","DOIUrl":"10.1016/j.gore.2025.101928","url":null,"abstract":"<div><h3>Introduction</h3><div>Ovarian cancer metastasis to the pericardium is rare. Surgical resection of such metastases is exceptionally uncommon, with only limited cases reported in the literature.</div></div><div><h3>Case Report</h3><div>We report a case of platinum-sensitive recurrent ovarian cancer treated with surgical resection, including massive diaphragmectomy and pericardiectomy. The surgery involved removing an 8 cm diaphragmatic lesion and a 5 cm pericardial defect, which was intentionally enlarged to 7 cm to prevent incarceration. A patch repair was used for the large diaphragm defect. Postoperatively, the patient recovered well and subsequently underwent chemotherapy and targeted therapy without complications.</div></div><div><h3>Conclusion</h3><div>Ovarian cancer metastasis to the central tendon of the diaphragm can involve the pericardium, requiring complex and high-risk surgery. Such cases necessitate a multidisciplinary approach led by a team of experienced gynecologic oncologists.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101928"},"PeriodicalIF":1.3,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}